Adrenal disease

Primary Aldosteronism Classification With 18-Oxocortisol and Gallium-68–Pentixafor Positron Emission Tomography/Computed Tomography

Endocr PractPublished Diagnostic accuracy study

Authors' conclusion

The LC-MS/MS and 68Ga-pentixafor PET/CT have great advantages on the subtyping of PA. There was a high accuracy of the combination of the 2 methods, which will contribute to avoid an unnecessary adrenal venous sampling operation before surgery for most patients with PA.

Study context

Population
Patients with primary aldosteronism (PA): 99 with aldosterone-producing adenoma (APA) and 61 with idiopathic hyperaldosteronism
Comparison
18-oxocortisol (LC-MS/MS) and 68Ga-pentixafor positron emission tomography (PET)/computed tomography (CT), alone or combined, for PA subtyping (APA vs idiopathic hyperaldosteronism)
Outcome
Diagnostic accuracy for APA vs idiopathic hyperaldosteronism

Performance

As reported in the abstract

Test or modelSensitivitySpecificity
18-oxocortisol75.3%91.2%
68Ga-pentixafor PET/CT visual analysis93.7%56.3%
68Ga-pentixafor PET/CT SUVmax69.8%93.7%

Sensitivity

18-oxocortisol75.3%
68Ga-pentixafor PET/CT visual analysis93.7%
68Ga-pentixafor PET/CT SUVmax69.8%

Specificity

18-oxocortisol91.2%
68Ga-pentixafor PET/CT visual analysis56.3%
68Ga-pentixafor PET/CT SUVmax93.7%
18-oxocortisol + PET/CT SUVmax double positive placed in right APA subtype
100%
18-oxocortisol + PET/CT visual analysis: sensitivity of at least 1 positive
95.2%
18-oxocortisol + PET/CT visual analysis: classified correctly
87.2%

Further findings

Steroid profiling (LC-MS/MS)

Average levels of 6 steroids apart from aldosterone higher in APA than idiopathic hyperaldosteronism

Original publication

Primary Aldosteronism Classification With 18-Oxocortisol and Gallium-68–Pentixafor Positron Emission Tomography/Computed Tomography. Endocr Pract. Published 25 February 2025. doi:10.1016/j.eprac.2025.02.012

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.